Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Ur Energy NYSEAMERICAN:URG$1.68 +0.07 (+4.01%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur EnergyMarket Capitalization$665.53 millionConsensus RatingBuyConsensus Price Target$2.57 (+52.3% Upside)Volume5.35 million sharesAverage Volume8.94 million sharesToday's Range$1.59▼$1.70 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. iBio NASDAQ:IBIO$1.90 +0.01 (+0.26%) As of 02:00 PM Eastern This is a fair market value price provided by Massive. Learn more.iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBioMarket Capitalization$94.64 millionConsensus RatingBuyConsensus Price Target$4.75 (+149.3% Upside)Volume295,765 sharesAverage Volume1.39 million sharesToday's Range$1.82▼$1.933. Inhibikase Therapeutics NASDAQ:IKT$1.74 -0.01 (-0.29%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. More about Inhibikase TherapeuticsMarket Capitalization$230.39 millionConsensus RatingBuyConsensus Price Target$5.50 (+215.2% Upside)Volume332,228 sharesAverage Volume1.44 million sharesToday's Range$1.70▼$1.794. Stereotaxis NYSEAMERICAN:STXS$1.96 -0.02 (-0.76%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about StereotaxisMarket Capitalization$193.04 millionConsensus RatingBuyConsensus Price Target$3.88 (+97.2% Upside)Volume164,196 sharesAverage Volume464,323 sharesToday's Range$1.91▼$1.985. Peraso NASDAQ:PRSO$1.10 -0.01 (-0.45%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Peraso Inc, a fabless semiconductor company, develops, markets, and sells semiconductor devices and modules. The company's products include millimeter wavelength (mmWave) ICs, including baseband IC, various mmWave radio frequency, integrated circuits, as well as associated antenna technology; and mmWave antenna modules. More about PerasoMarket Capitalization$16.29 millionConsensus RatingBuyConsensus Price Target$3.00 (+171.5% Upside)Volume618,020 sharesAverage Volume5.48 million sharesToday's Range$1.07▼$1.166. Biomea Fusion NASDAQ:BMEA$1.40 +0.02 (+1.09%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea FusionMarket Capitalization$100.86 millionConsensus RatingModerate BuyConsensus Price Target$8.29 (+494.0% Upside)Volume944,824 sharesAverage Volume1.37 million sharesToday's Range$1.33▼$1.437. Autolus Therapeutics NASDAQ:AUTL$1.88 +0.01 (+0.27%) As of 02:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus TherapeuticsMarket Capitalization$499.01 millionConsensus RatingModerate BuyConsensus Price Target$8.75 (+366.7% Upside)Volume1.16 million sharesAverage Volume1.75 million sharesToday's Range$1.76▼$1.888. Real Brokerage NASDAQ:REAX$1.82 +0.03 (+1.39%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.The Real Brokerage Inc, together with its subsidiaries, operates as a real estate technology company in the United States and Canada. More about Real BrokerageMarket Capitalization$389.64 millionConsensus RatingModerate BuyConsensus Price Target$5.69 (+211.6% Upside)Volume2.22 million sharesAverage Volume2.32 million sharesToday's Range$1.75▼$1.869. Nouveau Monde Graphite NYSE:NMG$1.92 -0.03 (-1.28%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Nouveau Monde Graphite Inc engages in the acquisition, exploration, development, and evaluation of mineral properties in Quebec, Canada. More about Nouveau Monde GraphiteMarket Capitalization$309.60 millionConsensus RatingModerate BuyConsensus Price Target$4.67 (+142.4% Upside)Volume443,059 sharesAverage Volume1.10 million sharesToday's Range$1.88▼$1.9410. Tenaya Therapeutics NASDAQ:TNYA$0.92 +0.06 (+6.33%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya TherapeuticsMarket Capitalization$200.51 millionConsensus RatingModerate BuyConsensus Price Target$4.00 (+332.9% Upside)Volume3.54 million sharesAverage Volume4.28 million sharesToday's Range$0.88▼$0.9511. MediciNova NASDAQ:MNOV$1.35 -0.01 (-0.74%) As of 02:00 PM Eastern This is a fair market value price provided by Massive. Learn more.MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. More about MediciNovaMarket Capitalization$66.45 millionConsensus RatingModerate BuyConsensus Price Target$7.50 (+455.6% Upside)Volume24,096 sharesAverage Volume54,969 sharesToday's Range$1.35▼$1.3612. Nano-X Imaging NASDAQ:NNOX$1.94 +0.02 (+0.78%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. More about Nano-X ImagingMarket Capitalization$134.66 millionConsensus RatingModerate BuyConsensus Price Target$5.00 (+158.4% Upside)Volume773,717 sharesAverage Volume1.27 million sharesToday's Range$1.81▼$1.9613. Senti Biosciences NASDAQ:SNTI$1.00 +0.05 (+4.98%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. More about Senti BiosciencesMarket Capitalization$31.06 millionConsensus RatingModerate BuyConsensus Price Target$8.75 (+775.9% Upside)Volume224,520 sharesAverage Volume197,521 sharesToday's Range$0.94▼$1.0214. Metagenomi NASDAQ:MGX$1.32 -0.04 (-2.57%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. More about MetagenomiMarket Capitalization$49.89 millionConsensus RatingModerate BuyConsensus Price Target$9.00 (+579.2% Upside)Volume112,906 sharesAverage Volume226,761 sharesToday's Range$1.30▼$1.3615. enCore Energy NASDAQ:EU$1.66 +0.06 (+3.75%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more.enCore Energy Corp. engages in the acquisition, exploration, and development of uranium resource properties in the United States. More about enCore EnergyMarket Capitalization$323.39 millionConsensus RatingModerate BuyConsensus Price Target$3.83 (+130.9% Upside)Volume1.88 million sharesAverage Volume3.00 million sharesToday's Range$1.56▼$1.6916. DeFi Technologies NASDAQ:DEFT$0.63 -0.02 (-3.38%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.DeFi Technologies, Inc engages in the provision of investment services. It plans to acquire equity, debt, or other securities of publicly traded or private companies or other entities. More about DeFi TechnologiesMarket Capitalization$243.31 millionP/E Ratio6.27Consensus RatingModerate BuyConsensus Price Target$2.00 (+218.5% Upside)Volume3.51 million sharesAverage Volume5.48 million shares17. Humacyte NASDAQ:HUMA$1.46 +0.16 (+11.92%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. More about HumacyteMarket Capitalization$323.04 millionConsensus RatingModerate BuyConsensus Price Target$6.43 (+341.8% Upside)Volume8.63 million sharesAverage Volume6.57 million sharesToday's Range$1.29▼$1.4718. SelectQuote NYSE:SLQT$1.02 +0.03 (+2.50%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more.SelectQuote, Inc operates a technology-enabled, direct-to-consumer distribution platform that sells a range of insurance products and healthcare services in the United States. More about SelectQuoteMarket Capitalization$180.76 millionP/E Ratio11.39Consensus RatingModerate BuyConsensus Price Target$3.00 (+192.7% Upside)Volume634,623 sharesAverage Volume1.69 million shares19. PepGen NASDAQ:PEPG$1.46 -0.04 (-2.33%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. More about PepGenMarket Capitalization$101.33 millionConsensus RatingModerate BuyConsensus Price Target$11.60 (+691.8% Upside)Volume300,501 sharesAverage Volume1.15 million sharesToday's Range$1.42▼$1.5220. SKYX Platforms NASDAQ:SKYX$1.16 +0.04 (+3.10%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more.SKYX Platforms Corp. provides a series of safe-smart platform technologies. The company's first and second-generation technologies enable light fixtures, ceiling fans, and other electrically wired products to be installed and plugged into a ceiling's electrical outlet box. More about SKYX PlatformsMarket Capitalization$156.67 millionConsensus RatingModerate BuyConsensus Price Target$5.00 (+329.2% Upside)Volume1.21 million sharesAverage Volume1.39 million sharesToday's Range$1.10▼$1.1721. ALX Oncology NASDAQ:ALXO$1.80 -0.10 (-5.00%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. More about ALX OncologyMarket Capitalization$242.88 millionConsensus RatingModerate BuyConsensus Price Target$4.60 (+154.8% Upside)Volume499,711 sharesAverage Volume848,128 sharesToday's Range$1.79▼$1.8922. Gain Therapeutics NASDAQ:GANX$1.94 -0.01 (-0.51%) As of 01:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$82.74 millionConsensus RatingModerate BuyConsensus Price Target$8.50 (+338.1% Upside)Volume797,393 sharesAverage Volume753,142 sharesToday's Range$1.90▼$2.0323. Pyxis Oncology NASDAQ:PYXS$1.80 0.00 (-0.22%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. More about Pyxis OncologyMarket Capitalization$113.97 millionConsensus RatingModerate BuyConsensus Price Target$6.83 (+280.5% Upside)Volume369,534 sharesAverage Volume637,723 sharesToday's Range$1.72▼$1.8424. ProQR Therapeutics NASDAQ:PRQR$1.46 -0.13 (-7.91%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$153.30 millionConsensus RatingModerate BuyConsensus Price Target$7.25 (+398.3% Upside)Volume504,745 sharesAverage Volume525,327 sharesToday's Range$1.46▼$1.5925. HeartBeam NASDAQ:BEAT$0.89 +0.02 (+2.06%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more.BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. More about HeartBeamMarket Capitalization$49.57 millionConsensus RatingModerate BuyConsensus Price Target$4.33 (+385.3% Upside)Volume268,274 sharesAverage Volume1.24 million sharesToday's Range$0.87▼$0.90 More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Alphabet Bets on Hardware With Googlebook and AI Glasses Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
